An interventional study of Triamcinolone acetonide injection and Fotona dynamis: Long pulse Nd YAG + Er YAG laser in Hypertrophic Scar, Keloid and Laser, sponsored by Somdech Phra Nangchao Sirikit Hospital. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Somdech Phra Nangchao Sirikit Hospital · Not applicable, Interventional, and Treatment
To compare the effectiveness of hypertrophic or keloid scar treatment with either intralesional corticosteroid injection alone or combined intralesional corticosteroid injection with either long-pulse ND YAG or Erbium YAG
129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.
This study's enrollment of 20 is below the median of 36 across 106 interventional studies indexed under Cicatrix, Hypertrophic.
Browse Cicatrix, Hypertrophic studies →This is the only study on the registry with Somdech Phra Nangchao Sirikit Hospital as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomly assigned keloid scar to each intervention (IL KA)
Drug: Triamcinolone acetonide injection
Randomly assigned keloid scar to each intervention (IL KA + ND YAG)
Device: Fotona dynamis: Long pulse Nd YAG + Er YAG laser
Randomly assigned keloid scar to each intervention (ILKA + Er YAG)
Device: Fotona Dynamis: Long pulse Nd YAG + Er YAG laser
Long-pulse ND YAG and Erbium YAG laser device: Fotona Dynamis
Intralesional corticosteroid injection combine with long-pulse Neodynium-doped Yttrium Aluminium Garnet Laser (Nd-YAG) (IL KA + ND YAG)
Intralesional corticosteroid injection combine with Erbium Yttrium Aluminium Garnet Laser (Er-YAG) (IL KA + Er YAG)
Vancouver scar scale
Vancouver scar scale to evaluate scar severity of keloid scar assessing 4 variations including vascularity, pigmentation, pliability, height scoring range from 0-13 (the more scores resembling the more severity)
Time frame: 5 months
Japan Scar Workshop Scar Scale
Japan Scar Workshop Scar Scale to evaluate scar severity of keloid scar assessing 2 main domains (risk factors and presenting symptoms) by 2 tables 1. Classification scoring range 0-5 = matured scars 6-15 = hypertrophic scars 16-25 = keloids 2. Evaluation for treatment \& follow ups scoring range from 0-18 (the more scores resembling the more severity)
Time frame: 5 months
Plan to share: Yes — Patient demographic data and scar characteristics, severity can be shared upon requests
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: 1st July 2025 - 31st Dec 2025
Access criteria: Patient demographic data and scar characteristics, severity can be shared upon requests by emailing to the main researchers and asking for permission
Data sharing details ↗ · drive.google.com
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.